Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Akebia Therapeutics (AKBA) Income towards Parent Company: 2016-2025

Historic Income towards Parent Company for Akebia Therapeutics (AKBA) over the last 9 years, with Sep 2025 value amounting to $540,000.

  • Akebia Therapeutics' Income towards Parent Company rose 102.69% to $540,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$15.9 million, marking a year-over-year increase of 65.42%. This contributed to the annual value of -$69.4 million for FY2024, which is 33.67% down from last year.
  • As of Q3 2025, Akebia Therapeutics' Income towards Parent Company stood at $540,000, which was up 118.62% from $247,000 recorded in Q2 2025.
  • Akebia Therapeutics' Income towards Parent Company's 5-year high stood at $29.0 million during Q2 2022, with a 5-year trough of -$84.3 million in Q2 2021.
  • Over the past 3 years, Akebia Therapeutics' median Income towards Parent Company value was -$11.2 million (recorded in 2023), while the average stood at -$10.4 million.
  • As far as peak fluctuations go, Akebia Therapeutics' Income towards Parent Company skyrocketed by 134.44% in 2022, and later slumped by 3,814.01% in 2024.
  • Quarterly analysis of 5 years shows Akebia Therapeutics' Income towards Parent Company stood at -$70.4 million in 2021, then surged by 90.76% to -$6.5 million in 2022, then skyrocketed by 109.44% to $614,000 in 2023, then slumped by 3,814.01% to -$22.8 million in 2024, then spiked by 102.69% to $540,000 in 2025.
  • Its Income towards Parent Company stands at $540,000 for Q3 2025, versus $247,000 for Q2 2025 and $6.1 million for Q1 2025.